At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
LENZ Therapeutics
Market Closed 03-21 16:00:00 EDT
26.49
+0.19
+0.72%
盘后26.49
+0.000.00%
16:22 EDT
| High26.75 | Low24.80 | Vol502.73K |
| Open25.81 | D1 Closing26.30 | Amplitude7.40% |
| Mkt Cap728.50M | Tradable Cap333.51M | Total Shares27.50M |
| T/O13.20M | T/O Rate3.99% | Tradable Shares12.59M |
| P/B-- | ROE-- | EPS0.00 |
| 52wk High-- | 52wk Low-- | P/E-- |
| Dividend-- | Div.Yield-- | ROA-- |
Loading ...
Buy Rating for Enliven Therapeutics Driven by Promising Market Dynamics and Growth Prospects
TIPRANKS · 03-22 13:35
Lenz Therapeutics’ Earnings Call Highlights Positive Outlook
TIPRANKS · 03-22 00:30
Cognition Therapeutics Earnings Call: Progress Amid Challenges
TIPRANKS · 03-22 00:23
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Business Wire · 03-21 20:15
Dyne Therapeutics Is Maintained at Neutral by JP Morgan
Dow Jones · 03-21 16:28
Summit Therapeutics Initiated at Overweight by Cantor Fitzgerald
Dow Jones · 03-21 14:24
Silexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer Conference
GlobeNewswire · 03-21 12:30
Enliven Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03-21 12:02
Context Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.
Dow Jones · 03-21 11:47
Century Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Simply Wall St. · 03-21 11:43
Cantor Fitzgerald Initiates Summit Therapeutics at Overweight
MT Newswires Live · 03-21 11:22
Rapport Therapeutics to Present Data at the 2025 American Academy of Neurology Annual Meeting
GlobeNewswire · 03-21 11:00
Positive Outlook and Buy Rating for Autolus Therapeutics Driven by Strategic Developments and Promising Prospects
TIPRANKS · 03-21 06:56
Coya Therapeutics Reports 2024 Financial Results and Progress
TIPRANKS · 03-21 04:05
Cognition Therapeutics Advances Alzheimer’s and DLB Trials
TIPRANKS · 03-21 04:04
Stoke Therapeutics Advances with Strong Financial Position
TIPRANKS · 03-21 04:04
Stoke Therapeutics Executives Make Major Moves in Stock Sales!
TIPRANKS · 03-21 02:04
VTv Therapeutics: Q4 Earnings Snapshot
Associated Press Finance · 03-20 22:00
Achilles Therapeutics Announces Voluntary Liquidation and Delisting
TIPRANKS · 03-20 21:59
Dyne Therapeutics Names Erick Lucera as CFO
MT Newswires Live · 03-20 21:35
Introduction
Company Name.
Therapeutics
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.
Issue price:
--
Invest in Global Markets with Tiger Brokers!Open App